Assessing the Benefit of NEPA (Fixed Combination of Netupitant/Palonosetron) for preventing Chemotherapy-induced Nausea and Vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy

被引：0

作者：

Karthaus, M. ^{[1
]}

Christoph, D. C. ^{[2
]}

Lux, M. P. ^{[3
]}

Hofheinz, R. -D ^{[4
]}

Jordan, K. ^{[5
]}

机构：

[1] Klinikum Neuperlach, Med Klin 4, Munich, Germany

[2] Evang Kliniken Essen Mitte, Essen, Germany

[3] Frauenklin St Vinzenz Krankenhaus, Paderborn, Germany

[4] UMM, Med 3, Mannheim, Germany

[5] Klinikum Ernst von Bergmann Hamatol Onkol & Palli, Potsdam, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P724

引用

页码：252 / 253

页数：2

共 50 条

[1] Assessing the benefit of NEPA (fixed combination of netupitant/palonosetron) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients at increased emetic risk receiving moderately emetogenic chemotherapy
Molasiotis, A.
Aapro, M. S.
Alonzi, A.
Chrapava, M.
Jordan, K.
Roeland, E. J.
Schwartzberg, L. S.
Terrasanta, C.
Olivari, S.
Dranitsaris, G.
ANNALS OF ONCOLOGY, 2022, 33 : 1546 - 1546
[2] Efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC)
Aapro, M.
Rossi, G.
Rizzi, G.
Borroni, M. E.
Lorusso, V.
Karthaus, M.
Grunberg, S.
EUROPEAN JOURNAL OF CANCER, 2013, 49 : S266 - S266
[3] Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV)
Navari, Rudolph M.
DRUG DESIGN DEVELOPMENT AND THERAPY, 2014, 9 : 155 - 161
[4] Efficacy of NEPA, a novel combination of netupitant (NETU) and palonosetron (PALO), for prevention of chemotherapy-induced nausea and vomiting (CINV) following highly emetogenic chemotherapy (HEC).
Hesketh, Paul Joseph
Rossi, Giorgia
Rizzi, Giada
Palmas, Marco
Alyasova, Anna
Drobner, Igor
Gralla, Richard J.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[5] Generic Netupitant Plus Palonosetron and Dexamethasone for Prophylaxis of Chemotherapy-Induced Nausea and Vomiting (CINV) in Cancer Patients Receiving Highly or Moderately Emetogenic Chemotherapy: A Retrospective Study
Simhadri, Soumya
Dayyala, Sowmya
Musinipally, Anjani Devi
Guram, Lavanya
Madavi, Mamatha
Kancha, Ramakrishna
Puligundla, Krishna Chaitanya
SOUTH ASIAN JOURNAL OF CANCER, 2024,
[6] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
Aapro, Matti S.
Rossi, Giorgia
Rizzi, Giada
Palmas, Marco
Grunberg, Steven
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[7] Phase III study of NEPA, a fixed-dose combination of netupitant (NETU) and palonosetron (PALO), versus PALO for prevention of chemotherapy-induced nausea and vomiting (CINV) following moderately emetogenic chemotherapy (MEC).
Aapro, Matti S.
Rossi, Giorgia
Rizzi, Giada
Palmas, Marco
Grunberg, Steven
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[8] NEPA <sc>(</sc>Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
Navari, Rudolph M.
Bonizzoni, Erminio
CANCER MEDICINE, 2025, 14 (07):
[9] Netupitant/palonosetron (NEPA) for prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in multiple cycles of chemotherapy.
Schwartzberg, Lee Steven
Gralla, Richard J.
Kashef, Kimia
Rugo, Hope
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (29)
[10] ANALYSIS OF PALONOSETRON VS ONDANSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PEDIATRIC PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
Kovacs, G.
Wachtel, A. E.
Basharova, E. V.
Spinelli, T.
Nicolas, P.
Kabickova, E.
PEDIATRIC BLOOD & CANCER, 2014, 61 : S108 - S108

← 1 2 3 4 5 →